Teva launches generic Lipitor sales in Canada

Sales of Pfizer's Lipitor in Canada total C$1.3 billion a year.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) subsidiary Teva Canada Inc. has obtained a Notice of Compliance from Health Canada to market its generic version of Lipitor tablets for lowering cholesterol.

Teva will begin shipments immediately.

Branded Lipitor is made by Pfizer Inc. (NYSE: PFE; LSE: PFZ). Brand sales in Canada total C$1.3 billion a year.

Teva's share price rose 0.3% on Nasdaq yesterday to $55.38, but fell 2% at the opening on the TASE today to NIS 212.60, in line with the general market slide.

Published by Globes [online], Israel business news - www.globes-online.com - on May 20, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters